{"id":11285,"date":"2026-08-14T16:41:47","date_gmt":"2026-08-14T14:41:47","guid":{"rendered":"https:\/\/ab-science.excalibra.com\/?page_id=11285"},"modified":"2026-09-29T10:35:47","modified_gmt":"2026-09-29T08:35:47","slug":"masitinib","status":"publish","type":"page","link":"https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/","title":{"rendered":"Masitinib"},"content":{"rendered":"

[vc_row gap=\u00a0\u00bb30px\u00a0\u00bb content_placement=\u00a0\u00bbmiddle\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbmas-hero-row\u00a0\u00bb][vc_column width=\u00a0\u00bb7\/12″ el_class=\u00a0\u00bbmas-hero-copy\u00a0\u00bb][vc_column_text]<\/p>\n

M\u00e9dicament en d\u00e9veloppement<\/p>\n

[\/vc_column_text][vc_column_text]<\/p>\n

Masitinib<\/h1>\n

IMMUNO-R\u00c9GULATION CIBL\u00c9E<\/p>\n

Une approche con\u00e7ue pour r\u00e9guler au plus juste les cellules impliqu\u00e9es dans la r\u00e9ponse immunitaire et accompagner le d\u00e9veloppement de traitements dans quatre indications prioritaires.<\/p>\n

[\/vc_column_text][\/vc_column][vc_column width=\u00a0\u00bb5\/12″ el_class=\u00a0\u00bbmas-hero-summary\u00a0\u00bb][vc_column_text]<\/p>\n

PROGRAMMES CLINIQUES<\/p>\n

4<\/div>\n

indications en cours de d\u00e9veloppement<\/h2>\n
3 \u00e9tudes de phase 3 \u00e0 initier1 \u00e9tude de phase 1 \u00e0 initier<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbmas-intro-section\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n

\n

Pr\u00e9sentation g\u00e9n\u00e9rale<\/p>\n

Une mol\u00e9cule au c\u0153ur de l\u2019immuno-r\u00e9gulation<\/h2>\n

Le masitinib est la mol\u00e9cule d\u2019AB Science la plus avanc\u00e9e. Il appartient \u00e0 une famille de m\u00e9dicaments appel\u00e9s inhibiteurs de kinases, des mol\u00e9cules qui bloquent certains signaux internes aux cellules. Il vise en particulier deux types de cellules du syst\u00e8me immunitaire inn\u00e9, les mastocytes et la microglie, dont l\u2019activation anormale entretient l\u2019inflammation dans diff\u00e9rentes maladies.<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]

<\/div>[\/vc_column][\/vc_row][vc_row el_class=\u00a0\u00bbmas-section-row\u00a0\u00bb][vc_column el_class=\u00a0\u00bbmas-mechanism-card\u00a0\u00bb][vc_column_text]<\/p>\n

M\u00c9CANISME D\u2019ACTION DU MASITINIB<\/p>\n

R\u00e9guler le \u00ab\u00a0nettoyage\u00a0\u00bb du syst\u00e8me immunitaire<\/h2>\n

[\/vc_column_text][vc_row_inner gap=\u00a0\u00bb34px\u00a0\u00bb content_placement=\u00a0\u00bbmiddle\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbmas-mech-top\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb5\/12″ el_class=\u00a0\u00bbmas-mech-copy\u00a0\u00bb][vc_column_text]<\/p>\n

Notre syst\u00e8me immunitaire comprend des cellules qui d\u00e9truisent les intrus, puis des cellules qui assurent le nettoyage des intrus d\u00e9truits. Ces derni\u00e8res appartiennent \u00e0 la famille des macrophages.<\/p>\n

Deux types de cellules sont en cause : les mastocytes, pr\u00e9sents dans l\u2019ensemble du corps, notamment le long des vaisseaux et du tube digestif, et les cellules microgliales, cellules immunitaires r\u00e9sidentes du cerveau. Lorsque le syst\u00e8me immunitaire s\u2019emballe, la r\u00e9action de nettoyage devient excessive et produit trop de mastocytes et\/ou de cellules microgliales.<\/p>\n

Leur pr\u00e9sence excessive peut g\u00e9n\u00e9rer plus de mal que de bien. L\u2019immuno-r\u00e9gulation consiste \u00e0 agir en amont pour limiter le nombre de cellules \u00ab\u00a0nettoyeuses\u00a0\u00bb au plus juste n\u00e9cessaire.<\/p>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb7\/12″ el_class=\u00a0\u00bbmas-mech-visual\u00a0\u00bb][vc_column_text]<\/p>\n

\"Illustration
De l\u2019\u00e9quilibre au d\u00e9sordre, puis \u00e0 la r\u00e9gulation.<\/figcaption><\/figure>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner]

<\/div>[vc_row_inner gap=\u00a0\u00bb18px\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbmas-step-grid\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/3″ el_class=\u00a0\u00bbmas-step-card\u00a0\u00bb][vc_column_text]<\/p>\n

01<\/p>\n

Une quantit\u00e9 normale<\/h3>\n

Une quantit\u00e9 normale de cellules mastocytes et\/ou microglies permet de faire correctement le m\u00e9nage des d\u00e9chets r\u00e9sultant de l\u2019action de notre syst\u00e8me immunitaire.<\/p>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/3″ el_class=\u00a0\u00bbmas-step-card mas-step-alert\u00a0\u00bb][vc_column_text]<\/p>\n

02<\/p>\n

Une quantit\u00e9 excessive<\/h3>\n

Une quantit\u00e9 anormalement \u00e9lev\u00e9e de mastocytes et\/ou de cellules microgliales ne permet pas de faire correctement le m\u00e9nage des d\u00e9chets r\u00e9sultant de l\u2019action de notre syst\u00e8me immunitaire\u2026 et g\u00e9n\u00e8re un d\u00e9sordre\u00a0: une inflammation qui se propage partout, \u00e0 l\u2019image de la poussi\u00e8re qui rend notre syst\u00e8me immunitaire inop\u00e9rant.<\/p>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/3″ el_class=\u00a0\u00bbmas-step-card mas-step-dark\u00a0\u00bb][vc_column_text]<\/p>\n

03<\/p>\n

La r\u00e9gulation par le masitinib<\/h3>\n

Le masitinib cible les mastocytes et les cellules microgliales. L\u2019hypoth\u00e8se \u00e9valu\u00e9e en phase 3 est qu\u2019en r\u00e9duisant l\u2019exc\u00e8s de ces cellules, il ralentisse la progression de la maladie.<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column]

<\/div>[\/vc_column][\/vc_row][vc_row el_class=\u00a0\u00bbmas-pathology-section\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n

M\u00c9CANISMES D\u2019ACTION PAR INDICATION<\/p>\n

Une action innovante pour chaque indication<\/h2>\n
\n

R\u00e9gulation de l\u2019inflammation<\/h3>\n

La neuroinflammation joue un r\u00f4le important dans les troubles neurod\u00e9g\u00e9n\u00e9ratifs tels que la scl\u00e9rose en plaques, la maladie de Charcot et la maladie d’Alzheimer. Le masitinib cible pr\u00e9cis\u00e9ment ces deux types de cellules, qui jouent un r\u00f4le cl\u00e9 dans la modulation de ce processus de neuroinflammation. L’activit\u00e9 pro-inflammatoire de ces cellules peut agir comme un catalyseur dans le processus neurod\u00e9g\u00e9n\u00e9ratif, ce qui sugg\u00e8re qu’il pourrait \u00eatre crucial de s’attaquer \u00e0 leur r\u00f4le n\u00e9faste dans le traitement de ces maladies. Le masitinib agit donc sur plusieurs indications par un m\u00e9canisme anti-inflammatoire.<\/p>\n<\/div>\n

[\/vc_column_text][vc_row_inner gap=\u00a0\u00bb18px\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbmas-pathology-grid\u00a0\u00bb]
\n[vc_column_inner width=\u00a0\u00bb1\/2″ el_class=\u00a0\u00bbmas-pathology-card mas-pathology-card–alzheimer\u00a0\u00bb][vc_column_text]<\/p>\n

Maladie d\u2019Alzheimer<\/h3>\n
\n

M\u00e9canisme d\u2019action<\/h4>\n

Dans la maladie d\u2019Alzheimer, les cellules du cerveau communiquent de moins en moins bien, puis finissent par mourir. Les points de contact entre neurones, les synapses, sont parmi les premiers \u00e9l\u00e9ments touch\u00e9s, et leur perte accompagne le d\u00e9clin de la m\u00e9moire. Autour d\u2019eux, la microglie et les mastocytes s\u2019activent et entretiennent une inflammation qui aggrave ces d\u00e9g\u00e2ts. La plupart des m\u00e9dicaments d\u00e9velopp\u00e9s dans cette maladie s\u2019attaquent aux d\u00e9p\u00f4ts de prot\u00e9ines anormales. Le masitinib suit une piste innovante : il agit sur ces cellules immunitaires du cerveau afin de calmer l\u2019inflammation et de pr\u00e9server les synapses.<\/p>\n

Donn\u00e9es pr\u00e9cliniques :<\/strong> dans des mod\u00e8les animaux, le masitinib a permis de restaurer des performances d\u2019apprentissage et de faire remonter les marqueurs de bonne sant\u00e9 des synapses.<\/p>\n<\/div>\n

\n

Stade de d\u00e9veloppement<\/h4>\n

Phase 3 \u00e0 initier<\/p>\n<\/div>\n

\n

R\u00e9sultats cliniques obtenus<\/h4>\n

Le masitinib a ralenti la d\u00e9t\u00e9rioration des fonctions cognitives chez les patients atteints de la maladie d’Alzheimer, avec m\u00eame une am\u00e9lioration des fonctions au cours de la p\u00e9riode de traitement de 24 semaines pour les patients atteints d’une maladie d\u2019Alzheimer l\u00e9g\u00e8re.<\/p>\n

Source : communiqu\u00e9 AB Science<\/a><\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″ el_class=\u00a0\u00bbmas-pathology-card mas-pathology-card–charcot\u00a0\u00bb][vc_column_text]<\/p>\n

Maladie de Charcot<\/h3>\n
\n

M\u00e9canisme d\u2019action<\/h4>\n

Dans la maladie de Charcot, ou scl\u00e9rose lat\u00e9rale amyotrophique (SLA), les motoneurones, ces cellules nerveuses qui commandent les muscles, d\u00e9g\u00e9n\u00e8rent progressivement. Autour d\u2019eux, des cellules du syst\u00e8me immunitaire s\u2019activent de fa\u00e7on anormale et entretiennent une inflammation qui acc\u00e9l\u00e8re cette d\u00e9g\u00e9n\u00e9rescence. Deux familles de cellules sont particuli\u00e8rement en cause : la microglie, qui r\u00e9side dans le cerveau et la moelle \u00e9pini\u00e8re, et les mastocytes, que l\u2019on retrouve le long des nerfs et jusque dans les muscles. Le masitinib agit en bloquant des enzymes appel\u00e9es kinases (principalement CSF-1R et c-Kit) qui commandent la multiplication et l\u2019activation de ces cellules. En les remettant sous contr\u00f4le, il vise \u00e0 r\u00e9duire l\u2019inflammation autour des motoneurones et \u00e0 pr\u00e9server plus longtemps la connexion entre le nerf et le muscle. Son originalit\u00e9 est donc d\u2019agir \u00e0 la fois dans le syst\u00e8me nerveux central et en p\u00e9riph\u00e9rie.<\/p>\n<\/div>\n

\n

Stade de d\u00e9veloppement<\/h4>\n

Phase 3 \u00e0 initier<\/p>\n<\/div>\n

\n

R\u00e9sultats cliniques obtenus<\/h4>\n

Parmi les survivants \u00e0 long terme trait\u00e9s par masitinib, la survie globale m\u00e9diane \u00e9tait de 121 mois, contre 42 mois pr\u00e9vus par le mod\u00e8le ENCALS, ce qui repr\u00e9sente un gain de survie m\u00e9diane r\u00e9siduelle de 79 mois<\/p>\n

Source : communiqu\u00e9 AB Science<\/a><\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″ el_class=\u00a0\u00bbmas-pathology-card mas-pathology-card–ms\u00a0\u00bb][vc_column_text]<\/p>\n

Formes progressives de la scl\u00e9rose en plaques<\/h3>\n
\n

M\u00e9canisme d\u2019action<\/h4>\n

La scl\u00e9rose en plaques se d\u00e9cline sous deux formes principales : la forme r\u00e9currente r\u00e9mittente, caract\u00e9ris\u00e9e par des pouss\u00e9es de la maladie, et la forme progressive, caract\u00e9ris\u00e9e par une aggravation constante et r\u00e9guli\u00e8re des sympt\u00f4mes de la maladie, sans pouss\u00e9e distincte ou p\u00e9riode de restauration.<\/p>\n

Dans la scl\u00e9rose en plaques, la gaine qui entoure et prot\u00e8ge les fibres nerveuses, appel\u00e9e my\u00e9line, s\u2019ab\u00eeme et l\u2019influx nerveux circule moins bien. Dans les formes progressives, le handicap s\u2019installe lentement et de fa\u00e7on continue, sans les pouss\u00e9es caract\u00e9ristiques des formes r\u00e9currentes. Les traitements existants agissent surtout sur le syst\u00e8me immunitaire dit adaptatif, celui des lymphocytes, ce qui explique en partie leur efficacit\u00e9 limit\u00e9e sur ces formes. Le masitinib emprunte une autre voie : il cible le syst\u00e8me immunitaire inn\u00e9, pr\u00e9sent en permanence dans le syst\u00e8me nerveux, en particulier la microglie et les macrophages, ainsi que les mastocytes. En freinant l\u2019activation de ces cellules, il cherche \u00e0 r\u00e9duire l\u2019inflammation qui use progressivement les fibres nerveuses et \u00e0 ralentir l\u2019installation du handicap.<\/p>\n<\/div>\n

\n

Stade de d\u00e9veloppement<\/h4>\n

Phase 3 \u00e0 initier<\/p>\n<\/div>\n

\n

R\u00e9sultats cliniques obtenus<\/h4>\n

Le masitinib a r\u00e9duit la progression du handicap de 37% (progression confirm\u00e9e \u00e0 3 mois). Le masitinib a significativement r\u00e9duit le risque d\u2019atteindre un niveau de handicap suffisamment s\u00e9v\u00e8re pour que les patients aient \u00e0 se d\u00e9placer en chaise roulante.<\/p>\n

Source : communiqu\u00e9 AB Science (en anglais)<\/a><\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″ el_class=\u00a0\u00bbmas-pathology-card mas-pathology-card–sickle\u00a0\u00bb][vc_column_text]<\/p>\n

Dr\u00e9panocytose<\/h3>\n
\n

M\u00e9canisme d\u2019action<\/h4>\n

La dr\u00e9panocytose est une maladie g\u00e9n\u00e9tique du globule rouge. L\u2019h\u00e9moglobine anormale qu\u2019il contient se rigidifie, le globule se d\u00e9forme et circule mal dans les petits vaisseaux. Ces obstructions, appel\u00e9es crises vaso-occlusives, provoquent des douleurs intenses et peuvent ab\u00eemer les organes. On sait aujourd\u2019hui que ce blocage n\u2019est pas seulement m\u00e9canique : l\u2019inflammation y joue un r\u00f4le actif, et les mastocytes, pr\u00e9sents dans la paroi des vaisseaux, en sont l\u2019un des moteurs. C\u2019est l\u00e0 qu\u2019intervient le masitinib, qui bloque les kinases commandant l\u2019activation de ces cellules. L\u2019objectif n\u2019est pas de corriger l\u2019h\u00e9moglobine anormale, mais de d\u00e9samorcer la r\u00e9action inflammatoire qui transforme la d\u00e9formation des globules rouges en crise douloureuse.<\/p>\n<\/div>\n

\n

Stade de d\u00e9veloppement<\/h4>\n

Phase 1 \u00e0 initier<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column]

<\/div>[\/vc_column][\/vc_row][vc_row full_width=\u00a0\u00bbstretch_row\u00a0\u00bb el_class=\u00a0\u00bbmas-status-band mas-pipeline-overview\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n
\n

INDICATIONS EN COURS DE D\u00c9VELOPPEMENT<\/p>\n

\n

Le statut actuel des programmes<\/h2>\n<\/div>\n
\n
\n\n\n\n\n\n\n\n\n
Mol\u00e9cule<\/th>\nAire th\u00e9rapeutique<\/th>\nIndication<\/th>\nStade de d\u00e9veloppement<\/th>\n<\/tr>\n<\/thead>\n
masitinib<\/span><\/td>\nMaladie neurod\u00e9g\u00e9n\u00e9rative<\/span><\/td>\nMaladie d\u2019Alzheimer<\/strong><\/td>\n\n
Phase 3 \u00e0 initier<\/i><\/div>\n<\/td>\n<\/tr>\n
masitinib<\/span><\/td>\nMaladie neurod\u00e9g\u00e9n\u00e9rative<\/span><\/td>\nMaladie de Charcot<\/strong><\/td>\n\n
Phase 3 \u00e0 initier<\/i><\/div>\n<\/td>\n<\/tr>\n
masitinib<\/span><\/td>\nMaladie neurod\u00e9g\u00e9n\u00e9rative<\/span><\/td>\nFormes progressives de la scl\u00e9rose en plaques<\/strong><\/td>\n\n
Phase 3 \u00e0 initier<\/i><\/div>\n<\/td>\n<\/tr>\n
masitinib<\/span><\/td>\nMaladie du sang<\/span><\/td>\nDr\u00e9panocytose<\/strong><\/td>\n\n
Phase 1 \u00e0 initier<\/i><\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Consulter le pipeline complet d\u2019AB Science<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]

<\/div>[\/vc_column][\/vc_row][vc_row el_class=\u00a0\u00bbmas-metric-section\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n

DUR\u00c9E DE CHAQUE \u00c9TUDE<\/p>\n

Des protocoles adapt\u00e9s \u00e0 chaque indication.<\/h2>\n

[\/vc_column_text][vc_row_inner gap=\u00a0\u00bb18px\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbmas-data-grid\u00a0\u00bb]
\n[vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Maladie d\u2019Alzheimer<\/p>\n

24<\/p>\n

semaines<\/p>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Maladie de Charcot<\/p>\n

48<\/p>\n

semaines<\/p>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Formes progressives de la scl\u00e9rose en plaques<\/p>\n

96<\/p>\n

semaines<\/p>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Dr\u00e9panocytose<\/p>\n

12<\/p>\n

semaines<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column]

<\/div>[\/vc_column][\/vc_row][vc_row full_width=\u00a0\u00bbstretch_row\u00a0\u00bb el_class=\u00a0\u00bbmas-patients-band\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n

POPULATION CONCERN\u00c9E \u2014 ESTIMATION \u00c9PID\u00c9MIOLOGIQUE<\/p>\n

Ampleur des besoins<\/h2>\n

[\/vc_column_text][vc_row_inner gap=\u00a0\u00bb18px\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbmas-data-grid mas-data-grid-on-blue mas-data-grid–population\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Maladie d\u2019Alzheimer<\/p>\n

5\u00a0millions<\/p>\n

de patients \u2014 Europe + \u00c9tats-Unis<\/p>\n

[\/vc_column_text][\/vc_column_inner]
\n[vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Maladie de Charcot<\/p>\n

50\u00a0000<\/p>\n

patients \u2014 Europe + \u00c9tats-Unis<\/p>\n

[\/vc_column_text][\/vc_column_inner]
\n[vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Formes progressives de la scl\u00e9rose en plaques<\/p>\n

500\u00a0000<\/p>\n

patients \u2014 Europe + \u00c9tats-Unis<\/p>\n

[\/vc_column_text][\/vc_column_inner]
\n[vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Dr\u00e9panocytose<\/p>\n

130\u00a0000*<\/sup><\/p>\n

patients \u2014 Europe + \u00c9tats-Unis<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_column_text]<\/p>\n

* 80\u00a0000 pour le continent africain<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=\u00a0\u00bbstretch_row\u00a0\u00bb el_class=\u00a0\u00bbmas-patients-band mas-market-section mas-needs-market-continuation\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n

POTENTIEL DE MARCH\u00c9 \u2014 ESTIMATION PAR INDICATION<\/p>\n

Potentiel de march\u00e9 estim\u00e9<\/h2>\n

[\/vc_column_text][vc_row_inner gap=\u00a0\u00bb18px\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbmas-data-grid mas-market-grid mas-data-grid-on-blue\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Maladie d\u2019Alzheimer<\/p>\n

environ 8<\/p>\n

milliards d\u2019euros \u2014 Europe + \u00c9tats-Unis<\/p>\n

[\/vc_column_text][\/vc_column_inner]
\n[vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Maladie de Charcot<\/p>\n

environ 1,5<\/p>\n

milliard d\u2019euros \u2014 Europe + \u00c9tats-Unis<\/p>\n

[\/vc_column_text][\/vc_column_inner]
\n[vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Formes progressives de la scl\u00e9rose en plaques<\/p>\n

environ 5<\/p>\n

milliards d\u2019euros \u2014 Europe + \u00c9tats-Unis<\/p>\n

[\/vc_column_text][\/vc_column_inner]
\n[vc_column_inner width=\u00a0\u00bb1\/4″ el_class=\u00a0\u00bbmas-data-col\u00a0\u00bb][vc_column_text]<\/p>\n

Dr\u00e9panocytose<\/p>\n

environ 2,5<\/p>\n

milliards d\u2019euros \u2014 Europe + \u00c9tats-Unis<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_column_text]<\/p>\n

Estimations communiqu\u00e9es par AB Science.<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row gap=\u00a0\u00bb30px\u00a0\u00bb content_placement=\u00a0\u00bbmiddle\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbmas-hero-row\u00a0\u00bb][vc_column width=\u00a0\u00bb7\/12″ el_class=\u00a0\u00bbmas-hero-copy\u00a0\u00bb][vc_column_text] M\u00e9dicament en d\u00e9veloppement [\/vc_column_text][vc_column_text] Masitinib IMMUNO-R\u00c9GULATION CIBL\u00c9E Une approche con\u00e7ue pour r\u00e9guler au plus juste les cellules impliqu\u00e9es dans la r\u00e9ponse immunitaire et accompagner le d\u00e9veloppement de traitements dans quatre indications prioritaires. [\/vc_column_text][\/vc_column][vc_column width=\u00a0\u00bb5\/12″ el_class=\u00a0\u00bbmas-hero-summary\u00a0\u00bb][vc_column_text] PROGRAMMES CLINIQUES 4 indications en cours de d\u00e9veloppement 3 \u00e9tudes de phase 3…<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":11294,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-11285","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nMasitinib – AB Science<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Masitinib\" \/>\n<meta property=\"og:description\" content=\"[vc_row gap=\u00a0\u00bb30px\u00a0\u00bb content_placement=\u00a0\u00bbmiddle\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbmas-hero-row\u00a0\u00bb][vc_column width=\u00a0\u00bb7\/12″ el_class=\u00a0\u00bbmas-hero-copy\u00a0\u00bb][vc_column_text] M\u00e9dicament en d\u00e9veloppement [\/vc_column_text][vc_column_text] Masitinib IMMUNO-R\u00c9GULATION CIBL\u00c9E Une approche con\u00e7ue pour r\u00e9guler au plus juste les cellules impliqu\u00e9es dans la r\u00e9ponse immunitaire et accompagner le d\u00e9veloppement de traitements dans quatre indications prioritaires. [\/vc_column_text][\/vc_column][vc_column width=\u00a0\u00bb5\/12″ el_class=\u00a0\u00bbmas-hero-summary\u00a0\u00bb][vc_column_text] PROGRAMMES CLINIQUES 4 indications en cours de d\u00e9veloppement 3 \u00e9tudes de phase 3…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-29T08:35:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ab-science.excalibra.com\/wp-content\/uploads\/2026\/08\/masitinib-regulation.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/masitinib\\\/\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/masitinib\\\/\",\"name\":\"Masitinib – AB Science\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/masitinib\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/masitinib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ab-science.excalibra.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/masitinib-regulation.png\",\"datePublished\":\"2026-08-14T14:41:47+00:00\",\"dateModified\":\"2026-09-29T08:35:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/masitinib\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/masitinib\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/masitinib\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/masitinib-regulation.png\",\"contentUrl\":\"https:\\\/\\\/ab-science.excalibra.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/masitinib-regulation.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/masitinib\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Public\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Masitinib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Masitinib – AB Science","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Masitinib","og_description":"[vc_row gap=\u00a0\u00bb30px\u00a0\u00bb content_placement=\u00a0\u00bbmiddle\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbmas-hero-row\u00a0\u00bb][vc_column width=\u00a0\u00bb7\/12″ el_class=\u00a0\u00bbmas-hero-copy\u00a0\u00bb][vc_column_text] M\u00e9dicament en d\u00e9veloppement [\/vc_column_text][vc_column_text] Masitinib IMMUNO-R\u00c9GULATION CIBL\u00c9E Une approche con\u00e7ue pour r\u00e9guler au plus juste les cellules impliqu\u00e9es dans la r\u00e9ponse immunitaire et accompagner le d\u00e9veloppement de traitements dans quatre indications prioritaires. [\/vc_column_text][\/vc_column][vc_column width=\u00a0\u00bb5\/12″ el_class=\u00a0\u00bbmas-hero-summary\u00a0\u00bb][vc_column_text] PROGRAMMES CLINIQUES 4 indications en cours de d\u00e9veloppement 3 \u00e9tudes de phase 3…","og_url":"https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/","og_site_name":"AB Science","article_modified_time":"2026-09-29T08:35:47+00:00","og_image":[{"url":"https:\/\/ab-science.excalibra.com\/wp-content\/uploads\/2026\/08\/masitinib-regulation.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/","url":"https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/","name":"Masitinib – AB Science","isPartOf":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/#primaryimage"},"image":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/#primaryimage"},"thumbnailUrl":"https:\/\/ab-science.excalibra.com\/wp-content\/uploads\/2026\/08\/masitinib-regulation.png","datePublished":"2026-08-14T14:41:47+00:00","dateModified":"2026-09-29T08:35:47+00:00","breadcrumb":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/#primaryimage","url":"https:\/\/ab-science.excalibra.com\/wp-content\/uploads\/2026\/08\/masitinib-regulation.png","contentUrl":"https:\/\/ab-science.excalibra.com\/wp-content\/uploads\/2026\/08\/masitinib-regulation.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ab-science.excalibra.com\/fr\/public\/masitinib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ab-science.excalibra.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Public","item":"https:\/\/ab-science.excalibra.com\/fr\/public\/"},{"@type":"ListItem","position":3,"name":"Masitinib"}]},{"@type":"WebSite","@id":"https:\/\/ab-science.excalibra.com\/fr\/#website","url":"https:\/\/ab-science.excalibra.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ab-science.excalibra.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ab-science.excalibra.com\/fr\/#organization","name":"AB Science","url":"https:\/\/ab-science.excalibra.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ab-science.excalibra.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/11285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/comments?post=11285"}],"version-history":[{"count":27,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/11285\/revisions"}],"predecessor-version":[{"id":11843,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/11285\/revisions\/11843"}],"up":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/11294"}],"wp:attachment":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/media?parent=11285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}